Cargando…

Cerebrospinal Fluid Amyloid β(1-42), Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson’s Disease

Parkinson’s disease (PD) is a neurodegenerative disease with heterogeneous pathological and clinical features. Cognitive dysfunction, a frequent non-motor complication, is a risk factor for poor prognosis and shows inter-individual variation in its progression. Of the clinical studies performed to i...

Descripción completa

Detalles Bibliográficos
Autor principal:	Kang, Ju-Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Movement Disorders Society 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886208/ https://www.ncbi.nlm.nih.gov/pubmed/27240810 http://dx.doi.org/10.14802/jmd.16017

Ejemplares similares

Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease
por: Dolatshahi, Mahsa, et al.
Publicado: (2018)

Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid(42) and DJ-1 in Human Cerebrospinal Fluid
por: Kruse, Niels, et al.
Publicado: (2016)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
por: Paterson, Ross W., et al.
Publicado: (2015)

Parkinson’s Disease Dementia: Synergistic Effects of Alpha-Synuclein, Tau, Beta-Amyloid, and Iron
por: Han, Jiajun, et al.
Publicado: (2021)

AlphaLISA detection of alpha-synuclein in the cerebrospinal fluid and its potential application in Parkinson’s disease diagnosis
por: Zhao, Hongli, et al.
Publicado: (2017)

Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels
por: Maxwell, Taylor J., et al.
Publicado: (2018)

Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ(1–42) and Tau Proteins in Elderly Patients With Mild Cognitive Impairment
por: Duron, Emmanuelle, et al.
Publicado: (2018)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
por: Bibl, Mirko, et al.
Publicado: (2012)

Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson’s Disease
por: Menéndez-González, Manuel, et al.
Publicado: (2018)

Preoperative cerebrospinal fluid β-Amyloid/Tau ratio and postoperative delirium
por: Xie, Zhongcong, et al.
Publicado: (2014)

The nonlinear relationship between cerebrospinal fluid Aβ(42) and tau in preclinical Alzheimer’s disease
por: de Leon, Mony J., et al.
Publicado: (2018)

β-Amyloid (1–42) Levels in Cerebrospinal Fluid and Cerebral Atrophy in Mild Cognitive Impairment and Alzheimer's Disease
por: Kaiser, Elmar, et al.
Publicado: (2011)

Corrigendum: Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aß(1−42), and Tau Proteins in Elderly Patients With Mild Cognitive Impairment
por: Duron, Emmanuelle, et al.
Publicado: (2019)

Cerebrospinal Fluid β-Amyloid(1–42) Levels in the Differential Diagnosis of Alzheimer’s Disease—Systematic Review and Meta-Analysis
por: Mo, Jin-A, et al.
Publicado: (2015)

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline
por: Emdina, Anna, et al.
Publicado: (2022)

α-Synuclein Aggregation Is Triggered by Oligomeric Amyloid-β 42 via Heterogeneous Primary Nucleation
por: Vadukul, Devkee M., et al.
Publicado: (2023)

Associations of sleep characteristics with alpha‐synuclein in cerebrospinal fluid in older adults
por: Wang, Xiao‐Tong, et al.
Publicado: (2020)

Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies
por: Poggiolini, Ilaria, et al.
Publicado: (2021)

Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders
por: Agnello, Luisa, et al.
Publicado: (2022)

Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels
por: Ibanez, Laura, et al.
Publicado: (2017)

Low cerebrospinal fluid Amyloid-βeta 1–42 in patients with tuberculous meningitis
por: Stroffolini, Giacomo, et al.
Publicado: (2021)

Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus
por: Patel, Sunil, et al.
Publicado: (2012)

Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment
por: Garrett, Stephanie L., et al.
Publicado: (2019)

Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid
por: Voyle, Nicola, et al.
Publicado: (2016)

Cerebrospinal fluid ratios with Aβ(42) predict preclinical brain β-amyloid accumulation
por: Racine, Annie M., et al.
Publicado: (2015)

Alpha-Synuclein and Cognitive Decline in Parkinson Disease
por: Fan, Tian-Sin, et al.
Publicado: (2021)

Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders
por: Constantinides, Vasilios C., et al.
Publicado: (2021)

Mini Review: Correlations of Cognitive Domains With Cerebrospinal Fluid α-Synuclein Levels in Patients With Parkinson's Disease
por: Murakami, Hidetomo, et al.
Publicado: (2021)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
por: Motta, Caterina, et al.
Publicado: (2023)

High cerebrospinal amyloid-β 42 is associated with normal cognition in individuals with brain amyloidosis
por: Sturchio, Andrea, et al.
Publicado: (2021)

Amyloid‐beta plasma and cerebrospinal fluid biomarkers in aged dogs with cognitive dysfunction syndrome
por: Stylianaki, Ioanna, et al.
Publicado: (2020)

Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease
por: Mollenhauer, Brit, et al.
Publicado: (2019)

The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders
por: Irwin, David J., et al.
Publicado: (2018)

Revisiting the Impact of Neurodegenerative Proteins in Epilepsy: Focus on Alpha-Synuclein, Beta-Amyloid, and Tau
por: Paudel, Yam Nath, et al.
Publicado: (2020)

Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ(1-42), T-tau, and P-tau values
por: Willemse, Eline A.J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1cv4vff7r3fp3cn4ajhrfvuvtg